Sanofi diabetes med offers freer schedule

Share this article:

New Phase-IIIb data about Sanofi's diabetes drug Lyxumia (lixisenatide) show that the drug may have flexible dosing on its side. The drug met the target of “non-inferiority in blood-sugar lowering” regardless of whether it was taken before breakfast or during what Sanofi calls “the main meal of the day,” which ended up being lunch for 53% of the patients in the 451-person clinical trial.

The daily GLP-1 injection is already marketed in Europe, Mexico, Australia and Japan, among other countries, but is in waiting mode in the US. The company pulled its FDA review request in September, saying it wanted its Elixa cardiovascular study to be completely wrapped before offering the drug up for US regulatory review.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.